XTL Biopharmaceuticals Ltd. (XTLB:NASDAQ) closed at $2.02 on October 23, 2026, up 2.54% on the day. The stock trades 64.2% below its 52-week high of $5.64 and 13.5% above its 52-week low of $1.78. Over the past year, it lost 58.9%. XTL Biopharmaceuticals Ltd. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since October 23, 2025, XTLB closed higher on 100 days (40%). Its best day was January 13, 2026 (+57.35%) and its worst was May 7, 2026 (-17.85%). The stock moved 10% or more in a single session 17 times. It opened at least 5% above the previous day's high 4 times.
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, is engaged in the acquisition and development of pharmaceutical products for the treatment of unmet medical needs. The company's lead drug candidate is hCDR1, a Phase II clinical trial product for the treatment of systemic lupus erythematosus related autoimmune process; and recombinant human erythropoietin (rHuEPO) for the treatment of multiple myeloma patients, as well as for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia. Its rHuEPO has also granted an orphan drug designation from the FDA for the treatment of multiple myeloma. The company is also developing SAM-101, a proprietary combination of antipsychotic drugs and a medicinal compound, which has completed Phase IIa clinical trials as a therapy for psychotic diseases with focus on schizophrenia. It has a licensing agreement with Yeda Research and Development Company for the development of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is based in Herzliya, Israel.
Find more stocks like XTLB with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.